Trupanion, Inc. filings document the company’s pet medical insurance business, public-company governance, and capital structure. Form 8-K reports include quarterly and annual operating results, with disclosures on subscription revenue, enrolled pets, net acquisition cost, adjusted EBITDA, operating cash flow, and other measures used to describe the company’s insurance economics.
The filing record also covers material agreements, including credit facilities, secured borrowings, maturity terms, covenants, and limits on corporate actions. Proxy materials document director elections, board composition, executive compensation, equity awards, shareholder voting matters, and related governance disclosures.
Trupanion, Inc. shareholder Margaret R. Tooth filed a notice of intention to sell common stock. The planned sale covers 978 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $28,410.90, to be sold on or after August 11, 2026 on NASDAQ. The disclosure also lists prior restricted stock awards and notes that 491 shares of common stock were sold for $10,733.26 on May 25, 2026.
Trupanion, Inc. reported an initial statement of beneficial ownership for Chief Marketing Officer Katherine Seawell. The Form 3 lists her as an officer but does not report any equity transactions or derivative positions in this filing.
Trupanion, Inc. reported Q2 2026 revenue of 392,934 (in thousands), up 11% year over year, with subscription revenue of 276,690 (in thousands) and other business revenue of 116,244 (in thousands). Subscription pets enrolled grew 5% to 1,124,548, while total pets enrolled declined 2% to 1,633,131 as lower-margin other business contracts ran off.
Operating income rose to 6,376 (in thousands) from 2,314 (in thousands), while net income was 6,831 (in thousands) versus 9,413 (in thousands) due to a prior-year nonmonetary exchange gain. For the first six months, revenue increased 12% to 776,983 (in thousands) and net income to 11,711 (in thousands). Monthly average revenue per subscription pet increased to 87.44 from 79.93, with average monthly retention at 98.37% and average pet acquisition cost rising to 299 from 276.
Cash, cash equivalents and restricted cash totaled 178,299 (in thousands) at June 30, 2026, alongside short-term investments of 249,131 (in thousands) and operating cash flow of 35,578 (in thousands) for the first half. Total principal on long-term debt was 107,500 (in thousands) under the PNC Facility. The board approved a new share repurchase program authorizing up to $100.0 million of common stock repurchases.
Trupanion reported second-quarter 2026 results with total revenue of $392.9 million, up 11% from a year earlier. Subscription business revenue grew to $276.7 million, up 14%. Total enrolled pets were 1,633,131, down 2%, while subscription pets rose 5% to 1,124,548.
GAAP net income for the quarter was $6.8 million, or $0.16 per basic and diluted share, compared with $9.4 million and $0.22 a year ago. Adjusted EBITDA increased to $19.8 million from $16.6 million. Operating cash flow was $21.0 million and free cash flow was $19.2 million, both higher than the prior year.
For the first six months of 2026, revenue was $777.0 million, up 12%, and net income was $11.7 million versus $7.9 million. Adjusted EBITDA was $37.1 million. At June 30, 2026, Trupanion held $398.5 million in cash and short-term investments and had $3.5 million available under its credit facility. In July 2026, an extraordinary $44 million dividend from its insurance subsidiary was approved, and the board authorized a share repurchase program of up to $100.0 million in common stock with no expiration, subject to factors including liquidity, credit facility compliance and market conditions.
TRUPANION, INC. Chief Operating Officer John R. Gallagher reported selling 431 shares of common stock on July 28, 2026 at $25.08 per share in an open-market transaction. After this sale, he directly holds 32,203 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 20, 2025, which limited his discretion over timing.
Trupanion, Inc. insider John Gallagher filed to sell common stock under a planned transaction. The filing lists 431 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an intended sale date of July 28, 2026.
The filing also reports prior sales of Trupanion common stock over the past three months, including 3,603 shares for $78,153.39 on May 28, 2026 and 431 shares for $10,925.85 on June 29, 2026. It references restricted stock positions dated August 25, 2023 and November 25, 2023.
TRUPANION, INC. Chief Operating Officer John R. Gallagher reported an open-market sale of 431 shares of Common Stock at $25.35 per share. After this transaction, he directly holds 32,634 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which set the timing in advance.
TRUP Form 144 notice relates to a proposed sale of Common stock by a holder through Morgan Stanley Smith Barney LLC as broker. The filing lists Restricted Stock (08/25/2023) as the class and shows recent reported sales: 3,603 shares on 05/28/2026 for $78,153.39; 431 shares on 04/28/2026 for $11,839.57; and 430 shares on 03/30/2026 for $10,952.10. Shares outstanding are shown as 43,620,472 as of 06/29/2026.
Trupanion, Inc. reported the results of its 2026 Annual Meeting of stockholders. Shareholders elected nine directors to serve until the 2027 annual meeting, with each nominee receiving over 30.4 million votes in favor and relatively small withheld amounts.
Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 34,886,804 votes for, 53,345 against and 21,092 abstentions. In an advisory, non-binding vote, shareholders approved 2025 compensation for the company’s named executive officers, with 30,437,067 votes for, 531,314 against and 24,126 abstentions.
TRUPANION, INC. executive Steve Weinrauch, EVP North America & Vet Strategy, reported an exercise-and-sell transaction in company stock. He sold 6,674 shares of common stock in an open-market sale at a weighted average price of $22.00 per share, with individual trades ranging from $21.95 to $22.04.
On the same date, he exercised 8,500 stock options with a $15.46 exercise price, converting them into common shares and fully exhausting that option grant. Following these transactions, Weinrauch directly owns 78,062 shares of Trupanion common stock.